DoD Peer Reviewed Orthopaedic, Applied Research Award | HT942524PRORPARA

Opportunity Information: Apply for HT942524PRORPARA

The DoD Peer Reviewed Orthopaedic Research Program (PRORP) Applied Research Award (ARA) is a Department of Defense grant opportunity focused on practical, near-term research that can improve treatment and functional recovery after major orthopaedic injuries, especially those tied to combat and military service. The core readiness problem driving the program is that extremity injuries make up about half of cases in the DoD Trauma Registry, and that non-combat musculoskeletal injuries and chronic orthopaedic conditions from training, old injuries, and everyday activity can be just as damaging to force readiness. The program emphasizes that timely stabilization, treatment, and rehabilitation can reduce complications, morbidity, and limb loss, and it values approaches that bring effective orthopaedic care as close to the point of injury as possible. While military relevance is central, the DoD is clear that results should also translate to civilian care and broadly benefit anyone who sustains significant orthopaedic trauma.

This ARA mechanism is specifically for applied, preclinical research rather than basic science or clinical studies. In the program language, applied research means taking promising concepts and turning them into potential solutions, then testing whether they are technically feasible and mature enough to move toward translation. Examples include developing or refining pharmacologic approaches, biologics, devices, diagnostic or therapeutic techniques, rehabilitation and behavioral interventions, clinical guidance, and other emerging technologies that could realistically progress toward patient impact. What it will not support is fundamental basic research aimed primarily at understanding underlying biology without a clear path to a product, process, or clinically relevant approach. It also will not support clinical research studies; applicants proposing clinical work are directed to other PRORP mechanisms such as the Clinical Translational Research Award, Clinical Trial Award, or the Womens Health Research Award.

The expected project scope can range from smaller efforts to larger applied programs, but the common expectation is that successful completion produces a concrete knowledge product, tool, approach, or technology positioned for the next translational step. A strong transition plan is a key competitiveness factor, meaning applicants should explain how the work will advance beyond the proposed project (for example, toward IND-enabling studies, device verification and validation, regulatory planning, or preparation for a later clinical trial). The solicitation also requires inclusion of relevant preliminary and/or published data; proposals need to show logical reasoning, a sound scientific rationale, and a clear, testable hypothesis grounded in a critical review of the literature. In practical terms, the DoD is looking for teams that can demonstrate the idea is already plausible and that the next set of experiments will reduce risk and move the solution closer to real-world use.

Within that applied, preclinical lane, the solicitation explicitly allows activities such as refining concepts into potential solutions or research tools, evaluating and maturing candidate products (including drugs, biologic constructs, and devices or systems) through in vitro and/or in vivo testing, and doing preparatory work that supports a future clinical trial or regulatory submission. The opportunity requires attention to rigorous experimental design and reproducibility standards, drawing on widely recognized best practices like randomization, blinding, sample size estimation, and clear data handling rules, consistent with guidance referenced from Landis et al. (Nature, 2012). If animal models are involved, applicants must include an Animal Research Plan and are expected to align planning and reporting with ARRIVE guidelines 2.0, reinforcing that the DoD wants preclinical findings that are credible, transparent, and more likely to translate.

The program also signals interest in womens health considerations and encourages applicants to analyze sex as a biological variable when relevant, particularly where orthopaedic injury mechanisms, recovery trajectories, or treatment responses may differ for women. Projects focused solely on womens health can be routed to the separate PRORP Womens Health Research Award, but the ARA itself welcomes strong integration of sex-based analysis when it strengthens the science and improves the relevance of outcomes.

On collaboration, military relevance is described as a defining feature and applicants are encouraged (though not required) to partner with Department of Defense and/or VA clinicians and researchers. If a project depends on DoD or VA resources or databases, the application must document access at submission and provide a plan to maintain that access throughout the period of performance, which is meant to reduce execution risk and prevent projects from stalling due to data or resource constraints.

Funding is provided as a grant under 31 USC 6304. Eligibility is listed as unrestricted. The total costs for the entire project period are expected not to exceed $750,000 per award. The Army contracting and assistance office listed is USAMRAA (Dept. of the Army). For the FY24 cycle, the DoD anticipated allocating about $3.75 million total to fund approximately five awards, with final funding dependent on federal fund availability, the number of applications received, and performance in peer and programmatic review. Awards supported with FY24 funds are expected to be made no later than September 30, 2025, and FY24 funds associated with awards are expected to remain available for use until September 30, 2030. The opportunity number is HT942524PRORPARA, CFDA 12.420, and the original closing date listed is September 17, 2024.

One notable boundary in the FY24 cycle is arthritis: with the launch of a separate Arthritis Research Program, the FY24 PRORP may not fund arthritis research itself. However, work addressing conditions or health abnormalities related to arthritis can be allowable if the project is still anchored to an eligible PRORP ARA Focus Area. In other words, arthritis cannot be the central target unless it is framed in a way that clearly fits the orthopaedic injury focus and the specific focus area requirements for this mechanism.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Applied Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-05-09.
• Applicants must submit their applications by 2024-09-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524PRORPARA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: